Here’s What Analysts Are Saying About Tenet Healthcare Corporation (THC) Post Earnings

Tenet Healthcare Corporation (NYSE:THC) is one of the best strong buy healthcare stocks to invest in. Truist lifted the price target on Tenet Healthcare Corporation (NYSE:THC) to $270 from $240 on February 17 and maintained a Buy rating on the shares, telling investors that it adjusted its model after the company released its fiscal Q4 financial results and 2026 guidance.

Tenet Healthcare Corporation (THC) Has Jim Cramer Seriously Worried Due To Medicaid Cutback

Wells Fargo also lifted the price target on Tenet Healthcare Corporation (NYSE:THC) to $265 from $229 on February 16, maintaining an Overweight rating on the shares. It stated in a post Q4 note that while the magnitude of the stock move on already previewed EBITDA and in-line guidance was “surprising,” strong capital return potential and alignment with key market narratives “appear to be important drivers.”

Tenet Healthcare Corporation (NYSE:THC) released its fiscal Q4 and full-year 2025 earnings on February 11, reporting that the net income available to common shareholders in fiscal Q4 was $371 million, or $4.22 per diluted share. Adjusted diluted earnings per share for the quarter rose 36.6% to $4.70 compared to $3.44 in the previous year period.

Tenet Healthcare Corporation (NYSE:THC) provides healthcare services, with its operations divided into the Hospital Operations and Ambulatory Care segments.

While we acknowledge the potential of THC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than THC and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.